Rx associated with fracture risk infrequently reduced after fracture occurrence

Is the occurrence of a fragility fracture -- where Medicare beneficiaries broke a hip, wrist or shoulder -- a missed opportunity to reduce exposure to prescription drugs associated with fracture risk?